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Abstract
Gastrointestinal symptoms are common in COVID-19 patients, especially in younger patients. Our hypothesis was that 
intestinal SARS-CoV-2 receptor ACE2 expression depends on patients’ age. We examined duodenal biopsies from 43 healthy 
human adults. ACE2 gene expression was directly correlated with age (Spearman’s r = 0.317, p = 0.039). With each year, 
duodenal ACE2 expression increased by 0.083 RU. The higher intestinal ACE2 mRNA expression in older patients may 
impact on their susceptibility to develop intestinal symptoms.
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Introduction
In December 2019, a novel infectious disease, caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was detected in Wuhan, China, causing the serious 
epidemic COVID-19 (Zhang 2020). Similar to the SARS 
coronavirus (SARS-CoV) that had caused outbreaks from 
2002 to 2004, SARS-CoV-2 binds via its spikes to its recep-
tor angiotensin-converting enzyme 2 (ACE2) with high 
affinity on cell surfaces (Hoffmann 2020; Walls 2020). This 
may enable SARS-CoV-2 to spread easily from person to 
person and make ACE2 a potential target for vaccines and 
therapies. ACE2 is abundantly present in humans on epithe-
lial cells of the lung (alveolar epithelial type II cells), kidney, 
heart, blood, and the small intestine (Hamming et al. 2004). 
In small intestinal enterocytes, ACE2 is necessary for the 
expression of luminal membrane amino acid transporters 
 B0AT1 (SLC6A19) and SIT1 (SLC6A20) (Vuille-dit-Bille 
2015; Meier 2018; Verrey 2009; Camargo 2009). The intes-
tine might therefore be an entry site for SARS-CoV-2, in 
particular when the protective role of gastric acid is reduced 
by drugs or surgically. Infection of human might even have 
started by eating food from the Wuhan market (Zhang 2020). 
The carboxymonopeptidase ACE2—similar to its structural 
homolog angiotensin-converting enzyme ACE—also acts 
as an enzyme that belongs to the renin–angiotensin system 
(RAS) and whose expression is induced in many tissues 
by application of RAS-active medications including ACE 
inhibitors (ACE-Is) and angiotensin II AT1 receptor block-
ers (ARBs). The increased ACE2 expression could facili-
tate infection with SARS-CoV-2. We previously showed in 
healthy human adults that ACE2 is expressed in the brush 
border membrane of small intestinal enterocytes, as well 
as in colonic crypts (Vuille-dit-Bille 2015). ACE2 mRNA 
expression was almost twice as high in patients treated 
with ACE-Is, when compared to patients without treat-
ment (Vuille-dit-Bille 2015). More recently we could show 
that ACE2 protein is also expressed in the brush border 
membrane of small intestinal enterocytes in human neo-
nates (aged 0–4 days) (Meier 2018). Small intestinal ACE2 
mRNA expression was almost 1.5 times higher in human 
adults versus neonates (Meier 2018).
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Methods
Duodenal biopsies were obtained from n = 43 healthy 
human adults undergoing routine upper endoscopies. 
Patients with gastrointestinal disorders and/or bleeding 
disorders, hepatic or kidney dysfunction and/or malignant 
disease were excluded. Tissue sampling, RNA extraction 
and real-time PCR analysis were performed as described 
elsewhere (Vuille-dit-Bille 2015).
Duodenal ACE2 mRNA expression was calculated 
relative to the housekeeping gene villin. The study was 
approved by the local ethics committee (EK-1744).
Correlation with different patient-related factors 
(including age, BMI, weight, height, diabetes mellitus, 
use of arterial blood pressure medications (ACE-Is and 
ARBs)) was assessed with Spearman’s rank correlation, 
and predictors of ACE2 mRNA expression were examined 
with univariable linear regression.
The effect of ACE inhibitors and angiotensin II AT1 
receptor blockers on intestinal ACE2 and amino acid 
transporter expression has been published elsewhere 
(Vuille-dit-Bille 2015).
Results
The baseline characteristics of the specimen donors are 
displayed in Table 1. The analysis of n = 43 specimens 
revealed that ACE2 gene expression was directly correlated 
with patient’s age (Spearman’s r = 0.317, p = 0.039; Fig. 1). 
In univariable linear regression, each increment (of a year) 
in age was related to an increase of the duodenal ACE 2 
mRNA expression of 0.083 RU. Patients < 60 years had a 
2.009 RU lower duodenal ACE 2 mRNA expression than 
patients 60 years and older. Age as scale variable, with an 
R2 of 0.173, showed a strong effect.
Age ranged from 22 to 77 years and did not significantly 
correlate with the use of ACE inhibitors (Spearman’s 
r = 0.268, p = 0.083). In Fig. 1, ACE 2 mRNA expression 
according to age was dichotomized for patients with (stars) 
and without ACE-I treatment (circles).
Discussion
The small bowel may be an important entry site for SARS-
CoV-2, as small intestinal enterocytes highly express 
ACE2 in the brush border membrane (Vuille-dit-Bille 
2015; Camargo 2009). Furthermore, viral mRNA may 
be detected in rectal swabs (even for a longer time period 
than in nasopharyngeal swabs) suggesting the possibility 
of fecal–oral disease transmission (Wang 2020; Xiao 
et  al. 2020; Holshue 2020). Reported gastrointestinal 
manifestations of COVID-19 are common and range from 
nausea and vomiting to diarrhea and abdominal discomfort 
with more than 10% of patients presenting with diarrhea (Jin 
2020; Gu et al. 2020). Gastrointestinal symptoms seem to 
be even more pronounced in children (Tian 2020; D’Amico 
et al. 2020). The pathophysiology of diarrhea in COVID-
19 patients remains unclear, but might be reflective of 
damage to the gastrointestinal tract and/or altered intestinal 
permeability resulting in malabsorption and diarrhea. As 
shown in the present study, small intestinal ACE2 mRNA 
expression correlates with age in healthy adults. In addition, 
we could recently show that small intestinal ACE2 mRNA 
expression in adults was about 1.5 times as high as in 
Table 1  Baseline characteristics
Age in years, median (IQR) 60 (49–66)
Male gender, N (%) 20 (46.5)
BMI in kg/m2, median (IQR) 26.3 (22.8–29.0)
Arterial blood pressure medications, N (%) 20 (46.5)
Fig. 1  Duodenal ACE 2 mRNA 
expression (relative to villin) 
according to the age of the 
n = 43 patients dichotomized for 
ACE inhibitor consumption
1065SARS-CoV-2 receptor ACE2 gene expression in small intestine correlates with age 
1 3
newborns, whereas its expression in older children has not 
been tested (Meier 2018). ACE2 is known to function as a 
brush border membrane-bound peptidase, and is required 
for the expression of amino acid transporters  B0AT1 
(SLC6A19) and SIT1 (SLC6A20) for which it functions 
as an associated chaperon protein (Vuille-dit-Bille 2015; 
Camargo 2009). It is noteworthy to mention that we have 
recently shown that the amino acid transporter SIT1 [similar 
to the fructose transporter GLUT 5 (SLC2A5)(Meier 2019)] 
is not yet expressed in newborn humans (Meier 2018), and 
that the association of ACE2 with amino acid transporters 
has been suggested to interfere with its proteolytic 
cleavage and thereby with its ability to support SARS-
CoV-2 infection (Yan 2020). Thus, differential amino acid 
transporter expression in children versus adults may impact 
on the susceptibility to intestinal SARS-CoV-2 infection. 
Additionally, the expression of ACE2 in small intestine 
may impact on the susceptibility to SARS-CoV-2-mediated 
infection and symptoms via its demonstrated effects on 
intestinal innate immunity and microbiota composition 
(Hashimoto 2012).
Taken together, our results suggest the possibility that 
age-dependent changes in intestinal ACE2 expression may 
impact on the susceptibility to gastrointestinal SARS-CoV-2 
infection and symptoms.
Limitations
Since the samples analyzed for this study were collected 
prior to the onset of the COVID-19 pandemic, intestinal 
ACE2 expression was not assessed in COVID-19 patients, 
and it was not determined whether older patients exhibit 
a higher viral load. Further studies are needed to analyze 
ACE2 mRNA and protein expression in intestinal samples 
of COVID-19 patients of different age groups and according 
to the severity of the disease.
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